1 Safe-and-Steady Stock to Target This Week and 2 We Find Risky

Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.

Luckily for you, StockStory helps you navigate which companies are truly worth holding. That said, here is one low-volatility stock providing safe-and-steady growth and two stuck in limbo.

Two Stocks to Sell:

Artivion (AORT)

Rolling One-Year Beta: 0.84

Formerly known as CryoLife until its 2022 rebranding, Artivion (NYSE:AORT) develops and manufactures medical devices and preserves human tissues used in cardiac and vascular surgical procedures for patients with aortic disease.

Why Do We Think Twice About AORT?

1. Subscale operations are evident in its revenue base of $405 million, meaning it has fewer distribution channels than its larger rivals
2. Lacking free cash flow generation means it has few chances to reinvest for growth, repurchase shares, or distribute capital
3. Below-average returns on capital indicate management struggled to find compelling investment opportunities

At $42.20 per share, Artivion trades at 57.5x forward P/E. To fully understand why you should be careful with AORT, check out our full research report (it’s free).

Labcorp (LH)

Rolling One-Year Beta: 0.48

With over 600 million tests performed annually and involvement in 90% of FDA-approved drugs in 2023, Labcorp (NYSE:LH) provides laboratory testing services and drug development solutions to doctors, hospitals, pharmaceutical companies, and patients worldwide.

Why Is LH Not Exciting?

1. Core business is underperforming as its organic revenue has disappointed over the past two years, suggesting it might need acquisitions to stimulate growth
2. Day-to-day expenses have swelled relative to revenue over the last five years as its adjusted operating margin fell by 14.3 percentage points
3. Diminishing returns on capital suggest its earlier profit pools are drying up

Labcorp’s stock price of $268.44 implies a valuation ratio of 16x forward P/E. Dive into our free research report to see why there are better opportunities than LH.

One Stock to Buy:

EXL (EXLS)

Rolling One-Year Beta: 0.79

Originally founded as an outsourcing company in 1999 before evolving into a technology-focused enterprise, EXL (NASDAQ:EXLS) provides data analytics and AI-powered digital operations solutions that help businesses transform their operations and make better decisions.

Why Should You Buy EXLS?

1. Annual revenue growth of 15.1% over the last five years was superb and indicates its market share increased during this cycle
2. Share buybacks catapulted its annual earnings per share growth to 25.5%, which outperformed its revenue gains over the last five years
3. Robust free cash flow margin of 11.5% gives it many options for capital deployment

EXL is trading at $42.07 per share, or 21.3x forward P/E. Is now the right time to buy? See for yourself in our in-depth research report, it’s free.

Stocks We Like Even More

When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.

Don’t let fear keep you from great opportunities and take a look at Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.